PCSK9 inhibitors in cancer patients treated with immune-checkpoint inhibitors to reduce cardiovascular events: new frontiers in cardioncology
V Quagliariello, I Bisceglia, M Berretta, M Iovine… - Cancers, 2023 - mdpi.com
Simple Summary Atherosclerosis is a critical cardiovascular disease associated with the use
of immune checkpoint inhibitors (ICIs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) …
of immune checkpoint inhibitors (ICIs). Proprotein convertase subtilisin/kexin type 9 (PCSK9) …
[HTML][HTML] Care Gaps and System Issues With Delivering Cardiovascular Risk Reduction and Lipid-Lowering Therapy in Secondary Prevention
G Marquis-Gravel, S Bhatia, V Brown… - Canadian Journal of …, 2024 - Elsevier
This article examines the care gaps in lipid-lowering therapy for atherosclerotic
cardiovascular disease (ASCVD), primarily focusing on discrepancies between …
cardiovascular disease (ASCVD), primarily focusing on discrepancies between …
Lipid-lowering drugs and inflammatory bowel disease's risk: a drug-target Mendelian randomization study
J Zhao, R Chen, M Luo, H Gong, K Li… - Diabetology & Metabolic …, 2024 - Springer
Background Inflammatory bowel disease (IBD) has been associated with lipid-lowering
drugs in observational studies. Drug-target Mendelian randomization (MR) was utilized in …
drugs in observational studies. Drug-target Mendelian randomization (MR) was utilized in …
Risk of atherosclerotic cardiovascular disease hospitalizations after chronic obstructive pulmonary disease hospitalization among older adults
CL Mosher, OL Osazuwa-Peters… - Annals of the …, 2024 - atsjournals.org
Rationale: Meta-analyses have suggested the risk of cardiovascular disease (CVD) events
is significantly higher after a chronic obstructive pulmonary disease (COPD) exacerbation …
is significantly higher after a chronic obstructive pulmonary disease (COPD) exacerbation …
Cholesterol Lowering in Older Adults: Should We Wait for Further Evidence?
Abstract Purpose of Review Current guidelines for primary and secondary prevention of
cardiovascular events in adults up to age 75 years are well-established. However …
cardiovascular events in adults up to age 75 years are well-established. However …
Implementation of risk-based lipid-lowering therapies in older (age≥ 65 years) and very-old adults (age≥ 75 years) with ischemic heart disease in the greater …
K Kopp, LJ Motloch, B Wernly, AE Berezin… - Frontiers in …, 2024 - frontiersin.org
Introduction: European guidelines recommend the implementation of lipid-lowering
therapies (LLTs) in adults (≥ 65 years) with established atherosclerotic cardiovascular …
therapies (LLTs) in adults (≥ 65 years) with established atherosclerotic cardiovascular …
Chronic Coronary Disease in Older Adults
AP Ambrosini, ES Fishman, AA Damluji… - Medical …, 2024 - medical.theclinics.com
Chronic coronary disease (CCD) is a major cause of morbidity and mortality in older adults.
1, 2 Despite this, older adults are underrepresented in the current literature supporting …
1, 2 Despite this, older adults are underrepresented in the current literature supporting …
[HTML][HTML] Risk of Atherosclerotic Cardiovascular Disease Hospitalizations after COPD Hospitalization among Older Adults
BACKGROUND: Meta-analyses have suggested the risk of atherosclerotic cardiovascular
disease (ASCVD) events is significantly higher after a chronic obstructive pulmonary …
disease (ASCVD) events is significantly higher after a chronic obstructive pulmonary …
[HTML][HTML] Trend of Controlled Low-Density Lipoprotein Cholesterol in Older Adults With a History of Myocardial Infarction or Stroke
THE CC BY-NC-ND LICENSE (http://creativecommons. org/licenses/by-nc-nd/4.0/). the
present study aligns with a large analysis of more than 500,000 MI hospitalizations that saw …
present study aligns with a large analysis of more than 500,000 MI hospitalizations that saw …